BERG is partnering with AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease.
Under this research arrangement, AstraZeneca will initially provide BERG with its curated library of central nervous system (CNS) optimized fragments to assist BERG in the discovery of candidates for therapeutic development.
BERG is working with Sanofi Pasteur, a global leader in influenza vaccines, to generate and model data using bAIcis® to assess potential biomarkers of seasonal influenza vaccination outcomes.
BERG Analytics and Becton, Dickinson and Company are are working together to focus on the development of a medication-adherence algorithm. This will help healthcare workers identify patient populations at risk of non-compliance for improved patient support post-discharge.